For these reasons, c-kit+ cells were used in the randomized clinical trial SCIPIO (Stem Cell Infusion in Patients with Ischemic cardiomyopathy), demonstrating a significant increase in left ventricular ejection fraction after one year of follow up in patients who received c-kit+ cells injection [153]. The gene discussed is KIT; the disease is ischemic cardiomyopathy.